Clinical Trial

Bioequivalence Study to Compare Imeglimin HCl 500 mg Film Coated Tablets Versus Twymeeg Tablets 500 mg

Completed Phase 1
View on ClinicalTrials.gov →
Summary
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, Two way crossover, Oral Bioequivalence Study of Imeglimin HCl 500 mg Film Coated Tablets of Humanis Sağlık A.Ş., Ç.O.S.B. Karaağaç Mahallesi Fatih Bulvarı No:32 Kapaklı/TEKİRDAĞ and Twymeeg Tablets 500 mg of Sumitomo Pharma Co., Ltd. 2-6-8, Dosho-machi, Chuo-Ward, Osaka City, in Healthy, Adult, Human Participants Under Fasting Condition.
Trial Details
NCT Number NCT07691177
Lead Sponsor Humanis Saglık Anonim Sirketi
Conditions Type 2 Diabetes
Enrollment 40 participants
Start Date 2026-02-06
Primary Completion 2026-03-27 (estimated)
Study Completion 2026-05-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-08